Combined therapy for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of chemotherapy, radiation, and an immunotherapy drug called tislelizumab before surgery for rectal cancer that has grown locally. The goal is to see if this approach can shrink the tumor more effectively and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer (a specific type called adenocarcinoma).
- Your tumor is locally advanced, meaning it has grown into nearby tissues but hasn't spread to distant organs.
- You are expected to be able to have surgery to remove the tumor after the treatment.
- You have not had any prior treatment for this cancer, such as surgery, chemotherapy, or radiation.
- You are generally healthy, with a performance status of 0 or 1 (meaning you can carry on your daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.